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1. Introduction 
An ideal glaucoma procedure is the one that is easy to perform, reproducible, with a low 
incidence of early postoperative hypotony, and long-term adequate IOP control. 
Furthermore, it should be minimally cataractogenic, allow rapid visual recovery and have 
the potential to be combined with phacoemulsification without one procedure potentially 
affecting the outcome of the other. Unfortunately, the quest for an ideal glaucoma procedure 
is on. The Landmarks in the course of surgical innovations for glaucoma management 
highlight the fact that we have come a long way.  
Landmarks in the history of surgical innovations for glaucoma 
• 1857 – Albrecht von Graefe: Surgical iridectomy “to reduce aqueous production” in 
glaucoma. Iridectomy helped many cases of angle closure, but not by the mechanism 
proposed. 
• 1859 – Coccius: Iridectomy with iris inclusion 
• 1876 – Argyll-Robertson: Scleral trephination 
• 1878 – Louis De Wecker: Anterior sclerectomy 
• 1903 – Bader and Lagrange: Iridosclerectomy 
• 1905 – Heine: Cyclodialysis 
• 1906 – Soren Holth: Iridenclesis 
• 1909 – Elliot: Corneoscleral trephination  
• 1924 – Preziozi: Electrocautery to create a full thickness fistula between the anterior 
chamber and the subconjunctival space. 
• 1936 – Otto Barkan: Goniotomy for chronic glaucoma in adults.  
• 1956 – Meyer-Schwickerath: Laser iridotomy with a xenon arc photocoagulator. 
• 1958 – Harold Scheie: Modified Preziozi’s procedure. Entered the eye with a knife and 
then used cautery to extend the scleral wound.  
•  1968 – Cairns: Trabeculectomy. Removed a rectangular section of trabecular meshwork 
and deep cornea. He aimed to remove a block of the canal of Schlemm to get aqueous to 
flow freely into its cut ends.  
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• 1968 – Anthony Molteno: Glaucoma drainage device that directly shunted aqueous 
from the anterior chamber into a episcleral reservoir. 
• 1976 – Theodore Krupin: First valved glaucoma drainage tube, at first without a 
reservoir. 
• 1979 – James B. Wise and Stanton L. Witter: Argon laser “trabeculoplasty.” 
• 1982 – Robert Ritch: Iridoplasty for acute angle closure crisis unresponsive to medication. 
• 1983 – Chen Wu Chen: Mitomycin C as an adjunctive in trabeculectomy.  
• 1984 – 5-Fluorouracil was first reported in an animal model and in a pilot study in 
glaucoma filtering surgery. 
• 2002 - ExPRESS miniature glaucoma shunt 
• 2003 - Reay Brown and Mary Lynch: EYEPASS glaucoma shunt 
• 2004 - George Baerveldt and Don Minckler: FDA approved, Trabectome 
microelectrocautery device 
• 2004 - Richard Hill and Mory Ghareb: Trabecular micro-bypass stent, iStent. 
Undergoing FDA review 
• 2005 – Deep light Gold shunt 
• 2009 - Bruce Shields: Aquashunt 
• 2009 - Transcend CyPass glaucoma implant 
2. Trabeculectomy 
Despite several available options, trabeculectomy—arguably is the most-performed glaucoma 
surgery till today. Although improved techniques and the adjunctive use of antimetabolites 
has enhanced long-term success as measured by intraocular pressure (IOP) control, 
trabeculectomy has a sizeable risk profile to glaucoma patients, over both the short and long 
term. 
Blebitis, bleb related endophthalmitis, hypotony, overfiltration, bleb leaks, bleb fibrosis and 
encapsulation, bleb overhang, corneal endothelial cell loss, dellen, and aqueous misdirection 
are among the many risks associated post trabeculectomy. (Borisuth et al, 1999) 
3. Drainage devices 
Glaucoma drainage devices (GDD) were initially developed for use in complex glaucoma 
patients, many of whom had failed medical, laser, and prior surgical treatments. (Molteno, 
1969; Krupin et al., 1976; Lloyd et al., 1994 & Coleman et al., 1995) Typically, these devices 
consist of a tube placed into the anterior chamber to allow for aqueous humor to flow 
posteriorly into an encapsulated filtration area typically 10–12 mm posterior to the limbus, 
into a reservoir sutured to the sclera. 
Though complications associated with anterior bleb formation were avoided, GDD resulted 
in a high risk of hypotony and overfiltration, sometimes leading to suprachoroidal 
hemorrhage. As a result several measures for flow restriction and regulation were adopted, 
but despite all efforts complication profile of GDD is significant. Overfiltration, fibrosis, tube 
exposure, tube occlusion, tube retraction and diplopia to list a few potential complications. 
(Kupin et al., 1995; Ticho and Ophir, 1993 & Gedde et al., 2007) 
Since neither trabeculectomy nor GDDs are without their fair share of complications, the 
quest for the development and advancement of glaucoma surgery to provide alternative 
means of shunting aqueous humor out of the anterior chamber is on.  
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Surgical procedures augmenting either conventional outflow pathway or uveoscleral 
outflow pathway have been developed. For conventional outflow enhancement, goniosurgical 
procedures (Epstein et al., 1985) and surgeries involving schlemm canal (both ab interno and 
ab externo) have recently emerged as successful surgical options.  
Surgical approaches to augment suprachoroidal outflow have also been explored with 
cyclodialysis, suprachoroidal implants, seton devices, and most recently, an ab externo gold 
shunt placed in the suprachoroidal space. (Pinnas and Boniuk, 1969; Krejci, 1972; Ozdamar 
et al., 2003; Jordan et al., 2006)  
 
Type Glaucoma surgery 
Non penetrating Viscocanalostomy 
Deep sclerectomy 
Canaloplasty 
Minimally penetrating Ex-PRESS glaucoma filtration device 
Trabecular micro-bypass iStent 
Trabectome microelectrocautery 
Gold microshunt (GMS) device  
Eyepass implant 
Penetrating Trabeculectomy 
Table 1. Types of glaucoma surgeries 
This chapter, addresses the available knowledge for the novel drainage devices; devices 
which attempt to assist with flow regulation such as the Ex-PRESS mini-glaucoma shunt 
(Alcon Laboratories, Inc., Fort Worth, TX) (Wamsley et al., 2004), Schlemm’s canal surgical 
procedures, including nonpenetrating canaloplasty surgery ( Lewis et al., 2007), the Glaukos 
trabecular micro-bypass iStent (Nichamin, 2009) the Trabectome microelectrocautery device 
(Nguyen, 2008) and the suprachoroidal outflow gold microshunt device (GMS) (Melamed et 
al., 2009) (Table 1).Published data is limited as many of these devices are currently in 
investigation and undergoing clinical trials.  
4. Minimally penetrating procedures 
4.1 Ex-PRESS glaucoma filtration device 
Ophthalmic surgery has evolved over the last several decades into sophisticated microsurgery 
involving continually smaller incisions. The Ex-PRESS shunt is on the forefront of this 
evolution toward smaller incision glaucoma filtration surgery. Since there is an added cost 
to using the Ex-PRESS rather than trabeculectomy, its place in the surgical management of 
glaucoma has not been clear so far. 
Device 
Ex-PRESS stands for “excessive pressure regulating shunt system”. 
The Ex-PRESS implant is a miniature unvalved glaucoma implant. It was originally 
developed by Optonol, Ltd. (Neve Ilan, Israel), as an alternative procedure to trabeculectomy 
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and to the other types of glaucoma filtering surgery for patients with open angle glaucoma 
(Nyska et al., 2003). Now, it is available as EX-PRESS Glaucoma Filtration Device (Alcon 
Laboratories, Inc., Fort Worth, TX).  
The device is approximately 3 mm long, stainless steel tube (outer diameter 400 μm (27 
gauge)) with a beveled, sharpened, rounded tip, a disc-like flange (<1 mm2) at the device 
proximal end, and a spur-like projection that prevents its extrusion. (Nyska et al., 2003; 
Geffen et al., 2010) The external flange and inner spur are angled to conform to the anatomy 
of the sclera, and the distance between them corresponds to the scleral thickness at the site 
of implantation. 
The EX-PRESS® Glaucoma Filtration Device is preloaded on a specially designed disposable 
introducer, the EX-PRESS® Delivery System (EDS). The EDS is an inserter designed to 
maintain the correct orientation of the EX-PRESS® Glaucoma Filtration Device throughout 
the implantation procedure. The commercially available versions are: R-50, P-50 and P-200. 
(Table 2; Figure 1) 
 
Characteristic Ex PRESS R50 Ex PRESS P50 Ex PRESS P200  
External body device  Round  Round  Round  
Device length  2.96  2.64  2.64  
Internal lumen size  50  50  200  
Tip shape  Pointed  Pointed  Pointed  
Backplate shape  Uniform  Vertical split  Vertical split  
Preincision needle gauge 27G  25G  25G  
Table 2. Comparative characteristics of the available models of Ex- PRESS implant 
Indications 
• Open Angle Glaucoma refractory to medical and laser treatment 
• Open Angle Glaucoma with a failed filtration procedure  
• Combined glaucoma and cataract procedure (Ex-PRESS may have the advantage of 
faster visual recovery compared with trabeculectomy) 
• Aphakic glaucoma (As no iridectomy is required with the Ex-PRESS implantation, there 
is less risk of vitreous moving forward through a new iridectomy) 
• Sturge-Weber syndrome and other situations as high hyperopia and nanophthalmos 
(Since chances of choroidal effusions following trabeculectomy are high in these subset 
of patients; Ex-PRESS implantation may offer a safer alternative because of its lower 
rate of prolonged postoperative hypotony) 
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Contraindications 
The implantation of the EX-PRESS® Glaucoma Filtration Device is contraindicated if one or 
more of the following conditions exist: 
• Presence of ocular disease such as uveitis, ocular infection, severe dry eye or severe 
blepharitis. 
• Pre-existing ocular or systemic pathology that, in the opinion of the surgeon, is likely to 
cause postoperative complications following implantation of the device. 
• Patient diagnosed with angle closure glaucoma. 
 
Scleral Slot
Accommodates the 
human scleral thickness
Axial Orifice
Main fluid conduit
3 Tranverse Orificies
Permit uninterrupted
aqueous humor flow
Shaft
27 gauge
0.4 mm diameter
Spur
Prevents device
extrusion
External Plate
Prevents intrusion
and occlusion
Penetreating Tip
En ables optimal
in sertion with minimal
damage to tissue
 
Fig. 1. R 50 Ex-PRESS device 
Surgical procedure 
Originally, the device was designed to be inserted at the limbus directly under the 
conjunctiva with formation of a subconjunctival bleb which served as a flow modulator. 
Poor conjunctival covering of the device, conjunctival erosions over the external flange and 
conjunctival scarring with subsequent decreased aqueous humour filtration, were some of 
the complications that were encountered because of direct subconjunctival implantation. 
(Kaplan Messa et al., 2002; Gandolfi et al., 2002; Traverso et al., 2005; Wamsley et al., 2004; 
Stewart et al., 2005; Rivier et al., 2007; Tavolato et al., 2006; Garg et al., 2005) 
Conjunctivoplasty or tube removal had to be performed to avoid secondary infection.  
To overcome these complications, Dahan and Carmichael suggested implanting the device 
under a limbus based 50% deep scleral flap extending into clear cornea. (Dahan and 
Carmichael, 2005) This operation is similar to standard trabeculectomy without the need of 
an iridectomy or scleral removal. 
This implant may also be used in deep sclerectomy to simplify the difficult dissection of 
Schlemm’s canal and Trabeculo-Descemet’s membrane. 
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4.2 Placement of device under a scleral flap 
To place the Ex-PRESS filtration device, a conjunctival peritomy, limbal or fornix-based, is 
first created as in conventional trabeculectomy. Gentle cautery is applied to the sclera prior 
to creation of a scleral flap. The dimensions of the scleral flap may need to be slightly larger 
than the trabeculectomy flap and it should be initiated more posteriorly in order to ensure 
full coverage of the shunt plate. 
Scleral spur is identified by a white, glistening band of fibers that crosses the bed of this 
section. The blue zone is a transition zone to the clear cornea. The surgeon should make sure 
that they implant the EX-PRESS device in the anterior chamber, just at the level of the scleral 
spur, but not too far posteriorly. It is important for the device to enter the eye exactly at the 
anterior aspect of the scleral spur and for it to remain at the iris plane so that it does not 
point downward towards the iris. 
Once the scleral spur has been visualized, the anterior chamber should be filled with 
viscoelastic or air in the area of anticipated shunt entry. Rather than an ostium created by a 
punch, trephine, or scissors, a 25- or 27-gauge needle or a 400 μm wide blade is used to enter 
the anterior chamber at the level of the scleral spur, parallel to the iris, and the Ex-PRESS 
device is injected into this needle tract. 
Complications 
The Ex-PRESS device relies on nonphysiologic subconjunctival flow as its mechanism of  
IOP lowering. As a result, all of the issues that limit trabeculectomy and the complication 
profile associated with blebs accompany the Ex-PRESS shunt too, but to a much lesser 
extent.  
Recently, external blockade of the tube has been reported as a possible device-related 
complication of Ex-PRESS implants, which can be visualized on a systematic gonioscopic 
examination. (Bagnis et al., 2011) It should be considered whenever IOP increases and a flat 
bleb is observed. Neodymium: Yttrium Argon Garnet (Nd:YAG) laser at the tip of the device 
is a viable therapeutic option to treat the external occlusion of Ex-PRESS devices, regardless 
the nature of the obstruction. Obstruction may also occur inside the lumen of the device 
where it may not be visualized by gonioscopy, at the point where the diameter constricts to 
50 mm. Since this constriction point is close to the opening into the anterior chamber, 
Nd:YAG laser works in this scenario as well (Netland, 2011). 
Corneal dislocation of the Ex-PRESS implant may occur and when associated with ocular 
hypertension, needs surgical treatment. (Vetrugno et al., 2011) Before considering a 
trabeculectomy, it could be valuable to attempt an implant reposition. Reopening of the 
conjunctiva and the scleral flap, excision of the corneal tissue covering the flange, and 
stitching the implant to the sclera with polyprolene suture has been tried with success. 
The Magnetic Resonance Imaging (MRI) systems in clinical use today operate with 
magnetic fields ranging from 0.2 to 3.0 Tesla. To ascertain MRI compatibility, the  
Ex-PRESS glaucoma drainage device (316L stainless steel) has been examined for 
magnetic field interactions under standard 1.5, 3.0, and 4.7 T MRI scanning protocols. 
(Seibold et al., 2011) During induced torque testing, no displacement was noted under 1.5 
and 3.0 T conditions, although a significant amount of displacement occurred in the 4.7 T 
environment. Increasing amounts of angular deflection were demonstrated at all three 
field strengths. So, it should be remembered that Ex-PRESS moves in the presence of high 
magnetic fields.  
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4.3 Scientific evidence so far 
Ex-PRESS versus trabeculectomy 
Maris et al in a retrospective comparative case series analysed data of 49 eyes with the  
Ex-PRESS and 47 eyes with a standard trabeculectomy. (Maris et al., 2007) The authors 
noted that although the mean IOP was significantly higher in the early postoperative period 
in the Ex-PRESS group compared with the trabeculectomy group, the reduction of IOP was 
similar in both groups after 3 months. The number of postoperative glaucoma medications 
in both groups was not significantly different. Kaplan-Meier survival curve analysis showed 
no significant difference in success between the two groups (P = 0.594). The success rate at 
an average of 11 months was 90% for the Ex-PRESS shunt compared with 92% for 
trabeculectomies at last follow up. Early postoperative hypotony and choroidal effusion 
were significantly more frequent after trabeculectomy than after Ex-PRESS implants under a 
scleral flap (P < 0.001). There was no difference between a limbal based or a fornix based 
approach with either procedure (trabeculectomy vs. Ex-PRESS shunt). After 3 months, the 
percentage decrease in IOP was similar for the groups, Ex-PRESS group (39.9 to 46.6%) and 
the trabeculectomy group (28.6 to 45.4%). For IOP control during the postoperative period,  
a significantly greater number of laser suture lysis procedures were performed in the  
Ex-PRESS group compared with the control group. The authors concluded that the  
Ex-PRESS implant under a scleral flap had similar IOP-lowering efficacy with a lower rate of 
early hypotony compared with trabeculectomy. 
Ex-PRESS in previously operated eyes 
Moster and co workers reported intermediate-term results of the Ex-PRESS implant (R-50 
and T-50), under a scleral flap in previously operated eyes (cataract or failed glaucoma 
surgeries). (Lankaranian et al., 2010) To compare the outcome between patients who had 
previous trabeculectomy or cataract surgery the definition of success was IOP of 5-15mmHg. 
One hundred eyes of 100 patients were studied. The mean follow-up period was 27 ± 13.2 
months (range: 12-66). Success was defined as complete if IOP was 5-21 mmHg without 
medication or surgical intervention, and qualified if IOP was within the same range with 
glaucoma medication. Success was complete in 60 (60%) and qualified in 24 (24%) eyes. The 
mean preoperative IOP of 27.7 ± 9.2 mm Hg (range, 14-52 mmHg) with 2.73 ± 1.1 drugs 
declined to 14.02 ± 5.1 mm Hg with 0.72 ± 1.06 drugs at the last follow up (P < 0.0001). The 
causes of failure were uncontrolled IOP (11%), bleb needling (4%), and persistent hypotony 
(1%). Bleb needling may induce an erratic wound healing response in some cases and lead 
to failure. The probability of success in the patients with previous cataract surgery and 
trabeculectomy at 3 years was 60.6% and 50.9%, respectively. Figure 2 shows Ex-PRESS 
implant in a case with previously failed trabeculectomy. 
Ates and coworkers studied 15 eyes with postpenetrating keratoplasty glaucoma unresponsive 
to medical antiglaucomatous therapy in which Ex-PRESS mini glaucoma shunt implantation 
was done. (Ates et al., 2010) 
IOP decreased from 41.46 mm Hg to 12.06 mm Hg over a mean follow-up of 12.2 months 
(P<0.001). 
IOP was below 21 mm Hg in 14 of 15 eyes (93.3%) with or without antiglaucomatous drugs. 
Complete success (IOP<21 mm Hg without medication) rate was 86.6%. Average number of 
antiglaucomatous drug usage decreased from 3.20 (range: 2 to 4) preoperatively to 0.26 
postoperatively (range: 0 to 3) (P<0.001). In 93.3% of the cases, the decrease in IOP was 30% 
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or above postoperatively. After Ex-PRESS implantation, clear grafts remained clear while 
edematous grafts became clearer due to IOP decrease. Neither biomicroscopy nor pachymetry 
showed worsening of preoperatively opaque grafts. 
Similarly, Vetrugno and colleagues also reported good results in vitrectomized patients who 
required glaucoma surgery for persistent ocular hypertension (Vetrugno et al., 2010). 
Ex-PRESS with deep sclerectomy 
Bissig and colleagues did a prospective, nonrandomized trial to study Deep Sclerectomy 
with the Ex-PRESS X-200 implant in 26 eyes. (Bissig et al., 2010) A posterior deep sclerectomy 
was dissected without opening the Schlemm's canal and an Ex-PRESS X-200 device was 
inserted under the scleral flap into the anterior chamber to drain aqueous humour into the 
intrascleral space. Eighty-five percent of patients achieved an IOP < 18 mmHg with or 
without medication and 69% without medication. Post-operative complications were 
hyphaema (15%), wound leak (15%), encysted blebs (54%) and bleb fibrosis in 8% of patients. 
 
 
Fig. 2. Ex-PRESS in a previously failed glaucoma surgery 
Gindroz and coworkers conducted a prospective study reporting on modified deep 
sclerectomy using the Ex-PRESS LR-50 in combined cataract and glaucoma surgery in 24 
eyes. (Gindroz et al., 2011) Preoperative data had, IOP: 18.1±5.3 mmHg, best-corrected 
visual acuity (BCVA): 0.6±0.3, and number of medications: 2.3±1.1. The IOP decreased by 
25.4% at 24 months and by 27.0% at 48 months. At 24 months, 19 patients (86.3%) achieved a 
BCVA of 0.5 or better, and at 48 months the mean BCVA was 0.7±0.3. At the last visit, the 
mean number of medications reduced to 0.6±0.8 (P<0.05). The complete and qualified 
success rates were 45.6% and 85.2%. No conjunctival erosions over the Ex-PRESS LR-50 
were noted. 
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Ex-PRESS with phacoemulsification 
Kanner and co workers implanted Ex-PRESS device under a scleral flap either as a single 
procedure in 231 eyes of 200 patients or combined with cataract surgery in 114 eyes of 100 
patients, for a total of 345 eyes in 300 patients who received the implant. (Kanner et al., 2009) 
They found that the Ex-PRESS implant under a scleral flap could lower IOP alone or in 
combination with cataract surgery. The most common device-related complication was 
blockage of the lumen of the implant, which was effectively treated with Nd:YAG laser 
treatment of the tube tip in the anterior chamber. 
4.4 Place in surgical armamentarium 
The advantages of this device as an adjunct to filtration surgery may be a lowered incidence 
of early postoperative hypotony and elimination of the need for a surgical iridectomy. The 
device is easily placed either temporally or nasally in an eye with prior scarring, as long as 
there are 2 to 3 clock hours of mobile conjunctiva available. There is often enough 
conjunctivae available between the side port vitrectomy scars to form a posterior bleb 
following a pars plana vitrectomy. Ex-PRESS requires less healthy tissue than for placement 
of a traditional drainage implant. 
Since the resulting blebs are usually low and diffuse, there is little risk of developing delle or 
bleb dysethesias, even when the surgery is located off to one side.  
In eyes with prior failed trabeculectomies, Ex-PRESS can help to reestablish the aqueous 
flow without having to repeat the original procedure. The Ex-PRESS fits easily in the middle 
ground between a repeat trabeculectomy and a larger glaucoma drainage device like a 
Baerveldt, Molteno, or an Ahmed tube shunt. 
Additionally, because of the technical familiarity of trabeculectomy, the learning curve for 
the incorporation of this device into filtering surgery is not a steep one, and it has shown to 
be effective when combined with phacoemulsification. 
Initial doubts about the Ex-PRESS filtration device are decreasing with recent advances 
offering possibly a wider spectrum of indications while diminishing the potential 
complications. 
5. Trabecular bypass devices 
The site of abnormal outflow resistance within the meshwork is probably the juxtacanalicular 
tissue adjacent to Schlemm’s canal, a layer of the meshwork approximately 10 µm thick. 
Removal or bypassing this thin layer of tissue should decrease the elevated IOP, without the 
need for creating a hole in the sclera and a filtration bleb. 
Recent work has focused on using small tubes to bypass the meshwork, creating a direct 
route from the anterior chamber into Schlemms’ canal. (Razeghinejad and Spaeth, 2011) 
5.1 Trabecular micro-bypass iStent 
Device 
The iStent® trabecular micro-bypass stent (Glaukos Corp, Laguna Hills, California) is the 
first ab-interno micro bypass stent. It is a heparin-coated with Duraflo (Edwards Lifesciences, 
Irvine, CA), nonferromagnetic, surgical grade titanium (Ti6Al4V ELI) stent less than one 
mm in length and approximately 0.3 mm in height, with a snorkel length of 0.25 mm and a 
nominal snorkel bore diameter of 120 μm. It is about 1/5000 of the size of the Baerveldt 
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implant. (Samuelson et al., 2011) The iStent® is inserted through a small temporal clear 
corneal incision, bypassing the trabecular meshwork, and placed in Schlemm's canal at the 
lower nasal quadrant. The dimensions of the stent are customized for a natural fit and 
retention within the 270μ canal space, with three retention arches to ensure secure placement. 
Indications 
• Mild-to-moderate primary open angle glaucoma 
• Pigmentary glaucoma 
• Pseudoexfoliative glaucoma, stand alone or in combination with cataract surgery. 
Contraindications 
• Presence of ocular disease such as uveitis, ocular infection 
• Patients diagnosed with angle closure glaucoma 
Surgical technique 
The iStent® is preloaded in a single-use, light release force, sterile applicator (Figure 3) with 
a secure, rotatable grip to facilitate manipulation and placement into Schlemm's canal. 
Separate orientations of the stent are available for the right and left eye. iStent® implantation 
can be performed under topical anesthesia. Prior to implanting the iStent®, the angle anatomy 
and targeted stent site must be in clear view. The Swan-Jacob gonioprism is used to inspect 
the angle to ensure a good view at the nasal implant location. The iStent® is implanted 
through the same small, temporal, clear corneal incision used for phacoemulsification or a 
1.5 mm incision when the stent is implanted as a stand-alone procedure. iStent in inserted in 
trabecular meshwork with “Penetrate, lift and slide” insertion technique. 
For best possible angle visualization; iStent® insertion should be performed from the 
temporal side with the microscope magnified 12X and tilted towards the surgeon. The 
patient's head is tilted away from the surgeon. 
  
Ø 120 μm 
1m
m
 
Fig. 3. Snorkel shaped iStent; iStent Applicator 
Implantation is performed in the nasal position (3 to 4 o'clock for the right eye; 8 to 9 o'clock 
for the left eye) with the tip of the implant directed inferiorly. The tip of the stent should 
approach the trabecular meshwork at 15° angle to facilitate penetration of the tissue (Figure 
4). Excessive resistance indicates that the approach is too perpendicular to the trabeculum. 
Once the stent is covered with meshwork it is released by pressing the applicator button. 
Only the proximal end of the stent remains visible in the anterior chamber. The iStent® is 
seated into position by gently tapping the side of the snorkel with the applicator tip. A small 
reflux of blood from the Schlemm's canal reflects correct positioning of the stent. Extraction 
of the viscoelastic material and hydration of the corneal incision conclude the procedure.  
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Proper stent placement is confirmed by flushing the anterior chamber of any refluxed blood, 
performing a high-magnification examination to confirm that the base of the implant is 
parallel with the circumferential axis of the Schlemm canal, and gently nudging the snorkel 
to confirm that the snorkel axis is parallel with the iris plane and that the base is well seated 
and fully through the trabecular meshwork. 
 
    
Fig. 4. Technique of iStent implantation 
Complications 
The stent is small (1 mm) and hence it may sometimes be difficult to verify exact placement 
of the implant via gonioscopy, particularly in cases of corneal edema, peripheral anterior  
synechiae, or an uncooperative or anxious patient. In such cases there is a possibility of 
accidentally misplacing the iStent. Ichhpujani and coworkers carried out an in vitro study, in 
which they used a human cadaver eye, unsuitable for transplantation, as a model to visualize 
the position of the stent. (Ichhpujani et al., 2010) They reported that in cases where gonioscopy 
is not successful, UBM can aid in localization of the iStent, in both the anterior and posterior 
chambers, provided the probe is moved to provide a favorable signal, whereas AS-OCT is 
limited to detection of stents in the anterior chamber alone and B-scan is of no value. 
A theoretical problem with bypass of the meshwork is blood reflux from Schlemm's canal 
into the anterior chamber via the tube, creating a microhyphema. Any activity that raises 
episcleral venous pressure higher than IOP, such as prolonged bending with the head down 
or vigorous Valsalva maneuver, would be most likely to cause this problem. Since such 
maneuvers also increase IOP by increasing the choroidal blood volume, this would counter 
the elevated episcleral venous pressure. This may explain why microhyphemas have not 
been reported till date with an iStent. 
5.2 Scientific evidence so far 
US iStent Study group assessed the safety and efficacy of the iStent in combination with 
cataract surgery in subjects with mild to moderate open-angle glaucoma. (Samuelson et al., 
2011) A total of 240 eyes with mild to moderate open-angle glaucoma with IOP ≤ 24 mmHg 
controlled on 1 to 3 medications were randomized to undergo cataract surgery with iStent 
implantation (treatment group) or cataract surgery only (control). The primary efficacy 
measure was unmedicated IOP≤ 21 mmHg at 1 year. The study met the primary outcome, 
with 72% of treatment eyes versus 50% of control eyes achieving the criterion (P< 0.001). At 
1 year, IOP in both treatment groups was statistically significantly lower from baseline 
values. Sixty-six percent of treatment eyes versus 48% of control eyes achieved ≥20% IOP 
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reduction without medication (P< 0.003). The overall incidence of adverse events was 
similar between groups with no unanticipated adverse device effects. 
The ocular hypotensive efficacy seen with the stent in this study was found to be consistent 
with the trabecular bypass mechanism of action and results described in literature. (Fea, 
2010; Spiegel et al., 2008 & 2009) 
Compared with cataract surgery alone, implantation of the iStent concomitant with cataract 
extraction significantly increases trabecular outflow facility, reduces IOP and the number of 
medications. (Fernandez- Barrientos et al., 2010) 
A study in cultured human anterior segments has shown that a single stent created the 
largest change in IOP, resulting in a mean of 12.4 ± 4.2 mm Hg, corresponding to an 84% 
increase in facility of outflow. Interestingly, IOP seemed to reach a baseline level of 
approximately 12 mm Hg, even with multiple stents. (Bahler et al., 2004) 
The probable explanation is that only one is enough to bypass the barrier of the Schlemm’s 
canal and the lumen of the iStent is large enough to drain the aqueous as if the Schlemm’s 
wall is well functioning. 
5.3 Place in the surgical armamentarium 
The iStent is believed to reestablish natural trabecular outflow, and it leaves the conjunctiva 
untouched, and avoids the lifelong risk of complications associated with filtering blebs. 
Thus, iStent implantation in patients with mild to moderate open-angle glaucoma undergoing 
cataract surgery represents a novel therapeutic approach that provides clinically significant 
reductions in IOP and medication use. 
5.4 Trabectome electrocautery device 
Device 
The Trabectome surgical device was cleared by the US Food and Drug Administration in 
January 2004 for the treatment of adult and juvenile open-angle glaucoma. The concept is 
similar in principle to ab interno trabeculotomy, the key difference being that a 
microelectrocautery device is used to ablate a strip of the trabecular meshwork and inner 
wall of Schlemm’s canal, thus allowing direct access of aqueous to the collector channels. 
This theoretically bypasses the main site of resistance to aqueous outflow and reestablishes 
the natural drainage passageway out of the eye. 
The Trabectome consists of a disposable footpedal activated handpiece and a console to 
adjust infusion, aspiration and electrosurgical energy. The handpiece consists of a 19-gauge 
infusion sleeve, a 25-gauge aspiration port, and a bipolar electrocautery unit 150 μm away 
from an insulated footplate (Figure 5). The footplate is 800 μm in length from the heel to the 
tip, has a maximum width of 230 μm, and maximum thickness of 110 μm. 
Indications 
Trabectome may be an excellent surgical option for patients who require postoperative IOPs 
in the mid-to-high teens. It can be combined with cataract surgery.  
• Early to moderate Primary open-angle glaucoma 
• Pigmentary and pseudoexfoliative glaucoma.  
• Patients with elevated IOP despite previous glaucoma surgery (trabeculectomy or a 
drainage tube)  
www.intechopen.com
 Novel Glaucoma Surgical Devices 
 
429 
Contraindications 
Angle closure with or without peripheral anterior synechiae is the only contraindication. 
Trabecular meshowork without pigment may pose difficulty for proper gonioscopic 
identification of structures. 
 
Width: 230 μm
Thickness: 110 μm
Length: 800 μm
  Return
Electrode
Insulating Shoe
  Active
Electrode
 
Fig. 5. Trabectome hand piece 
Surgical procedure 
Surgery is carried out with a temporal approach through a clear corneal incision of 1.6-1.8 
mm to accommodate the electrocautery unit. Alternatively, when combined with clear 
cornea coaxial phacoemulsification, the main incision may be used for the Trabectome 
handpiece. Ophthalmic visco-devices are used to inflate and stabilize the anterior chamber 
and a gonioprism is used for direct visualization of the angle. Once the instrument has been 
inserted into Schlemm’s canal, the foot pedal is depressed to begin electrocautery. The 
surgeon’s hand simultaneously moves in one direction to ablate the tissue until the tip of the 
handpiece has reached the limit of visibility. The handpiece may then be turned to achieve 
ablation in the opposite direction again, to the limits of view. Total arc length amenable to 
treatment through a single incision is 60–90°. Tissue debris released during electrocautery 
can obscure the view hence aspiration and continuous irrigation are carried out. A clear 
corneal suture is applied and intracameral air is injected at the conclusion of Trabectome 
ablation to prevent postoperative hyphema. 
When combined Trabectome and cataract surgery are done then the ab interno 
trabeculotomy is completed before starting the phacoemulsification. This order of operation 
prevents the formation of phacoemulsification-related corneal edema that could impair 
visualization of the angle structures. 
Too low power settings and rapid movement of the handpiece should be avoided as it may 
lead to inadvertent tear of the trabecular meshwork and cause tissue from the inner wall of 
Schlemm's canal to accumulate in the gap of the footplate. In addition, the surgeon should 
make sure that the eye does not rotate during the treatment, as this indicates excessive 
pressure on the posterior wall of Schlemm's canal. 
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Many surgeons advocate the use of pilocarpine 1% 1 to 2 hours prior to Trabectome-only 
surgery to improve surgical visualization of the angle and to protect the crystalline lens in 
phakic patients. Postoperatively, pilocarpine can enhance aqueous outflow and prevent the 
development of peripheral anterior synechiae. The tapering of glaucoma medications is 
generally undertaken approximately 1 month after surgery. 
The procedure has a learning curve, especially for surgeons not familiar with operating 
temporally or with various patient head positions. 
Complications 
Transient hyphemas are the typical complication, clearing within a few days. Other 
complications are rare in this procedure, but can include iridodialysis, cyclodialysis, and 
IOP spike. Sustained hyphema, wound leak, infection, choroidal effusion, and hemorrhage 
are not typically seen after this procedure. 
5.5 Scientific evidence so far 
Minckler et al reported a retrospective case series of 1127 Trabectome surgeries, with 738 
Trabectome-only and 366 Trabectome-cataract surgeries. (Minckler et al., 2008) Overall, IOP 
reduced to 39% at 24 months (n=50), and with Trabectome only cases (n=46) the reduction 
was 40%. Surgery combined with cataract removal (n=45) showed an 18% decrease in IOP at 
12 months. Medications were decreased by at least half in each cohort. 
Francis et al for the Trabectome study group reported the short-term results of combined 
phacoemulsification and trabeculotomy by the internal approach with a follow-up to 21 
months. (Francis et al., 2008) This prospective interventional case series comprised of 304 
consecutive eyes with open-angle glaucoma and cataract having combined 
phacoemulsification and trabeculotomy with a Trabectome. The mean IOP was 20.0 mm Hg 
±6.3 (SD) preoperatively, 14.8±3.5 mm Hg at 6 months, and 15.5±2.9 mm Hg at 1 year. There 
was a corresponding drop in glaucoma medications from 2.65±1.13 at baseline to 1.76±1.25 
at 6 months and 1.44±1.29 at 1 year. Subsequent secondary glaucoma procedures were 
performed in 9 patients. The only frequent complication, blood reflux in 239 patients 
(78.4%), resolved within a few days.  
Previous laser trabeculoplasty does not appear to significantly impact IOP, but may increase 
the need for glaucoma medication in patients undergoing Trabectome surgery (Vold and 
Dustin, 2010). 
5.6 Place in surgical armamentarium 
Early clinical experience with this technology has shown that patient selection, surgical 
technique, and postoperative medical management affect patients' outcomes. Though it is 
efficacious in IOP lowering, we still do not know what is the maximal amount of IOP 
lowering that can be attained, and whether this relates to other factors such as episcleral 
venous pressure. 
5.7 Canaloplasty 
Canaloplasty is an ab externo procedure which entails 360° intubation of Schlemm’s canal, 
along with suture-assisted distension of the canal in order to restore physiologic outflow via 
the conventional pathway without the formation of a fistula or bleb (Khaimi, 2009). The 
iTrack 250 flexible microcatheter (iScience Interventional, Menlo Park, CA) for canaloplasty 
received FDA approval in 2008. 
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Device 
The iScience device has a 45-mm working length flexible polymer microcatheter of 200-mm 
shaft diameter with a rounded 250-mm tip diameter (Figure 6).The catheter consists of a 
central support wire designed to provide a backbone for guidance during advancement and 
to add resistance to potential kinking of the microcatheter. The optical fibers in the 
microcatheter allow for transmission of a red blinking light from a laser-based micro-
illumination system to the tip to assist in visualization and localization of the tip during 
passage. The microcatheter possesses a true lumen for the delivery of substances such as 
viscoelastic to expand the canal during passage or retraction. The proximal end of the device 
connects to the nonsterile laser-based micro-illumination light source on a mayo stand from 
one arm, with another arm connected to a sterile screw-mechanism syringe designed to 
assist in controlled injection of viscoelastic into Schlemm’s canal. 
 
Optical fiber, light transmision
Catheter support wire
                                                Lumen
Polymer shaft and distal atraumatic tip
 
Fig. 6. iTrack250A canaloplasty microcatheter 
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Indications 
• Mild-to-moderate open angle glaucoma 
• Pigmentary glaucoma (Ichhpujani et al., 2011) 
• Pseudoexfoliative glaucoma 
Contraindications 
• Scarring from prior trabeculectomy  
• Patients with obvious scarring in Schlemm’s canal due to prior medication use, laser, 
surgery or corneoscleral trauma at the limbus 
• Anomalies in the anterior chamber angle 
Surgical procedure 
The chosen surgical site is the superior sclera and hence a traction suture is needed for 
maintaining a downgaze position. For a corneal traction a careful site selection is required so 
as to ensure the suture is placed several clock hours away from the intended surgical site. 
A fornix based conjunctival peritomy is done leaving an anterior skirt of conjunctiva attached 
to the limbus with blunt dissection carried out posteriorly. Light wet field cautery is applied 
to the sclera, being careful to avoid aqueous and ciliary veins. A superficial parabolic scleral 
flap of approximately 5 mm anterior–posterior length by 5 mm width and one-third scleral 
thickness is fashioned with the help of a crescent knife, forward into clear cornea. A 
deep inner scleral flap is then created approximately 1 mm inside from the edge of the 
superficial scleral flap. An approximately 100 mm thick layer of sclera should be left 
covering the choroid at the base of the deep dissection. Once the white limbus-parallel fibers 
of the scleral spur are visible at the deep dissection, fibers of the outer wall of Schlemm’s 
canal should be visible by lifting of the deep flap with a toothed forceps. A paracentesis 
incision should be made in the clear cornea to lower the IOP to prevent outward bulging of 
Descemet’s membrane and the inner wall of Schlemm’s canal, reducing the likelihood of 
penetration into the anterior chamber during the ensuing delicate dissection. The deep flap 
is now advanced forward approximately another 1 mm to expose Descemet’s membrane. 
Mermoud forceps can be used to delicately strip the inner wall of Schlemm’s canal away. 
The corneal stroma should be separated from Descemet’s window with surgical sponges 
such as Merocel. Once the window has been fashioned, the underside of the deep flap is 
scored with a sharp tip blade at the very anterior aspect and cut off with Vannas scissors. 
Each cut end of Schlemm’s canal is then intubated with a 150-mm outer bore viscocanalostomy 
cannula, and a miniscule amount of high viscosity sodium hyaluronate is injected into each 
end to dilate the ostia and facilitate entrance of the iScience device into the canal.  
With the help of nontoothed forceps, the microcatheter is introduced into one of the cut ends 
of Schlemm’s canal and advanced 360° until the tip emerges from the other cut end of the 
canal. In a minority of patients successful catheterisation through the entirety of the canal 
fails. At times the microcatheter may pass into the suprachoroidal space posterior to 
Schlemm’s canal. In such cases, the catheter should be immediately retracted and passage 
attempted in the opposite direction. Once the microcatheter has been passed 360° and the tip 
has emerged, a 10–0 Prolene suture with the needles cut off is tied around the shaft of the 
device near the tip with the two loose ends tied to the loop. The device is then withdrawn 
slowly from the opposite direction with controlled injection of viscoelastic every 2-3 clock 
hours, taking care not to cause Descemet’s detachment. 
Once the catheter has been removed, the 10–0 Prolene is cut from the tip, leaving two single 
10–0 Prolene sutures in the canal with two loose ends emerging from each cut end of 
www.intechopen.com
 Novel Glaucoma Surgical Devices 
 
433 
Schlemm’s canal. Each suture is tied to itself in a slipknot fashion with some back and forth 
movement in the canal, known as “flossing, ” to ensure that the suture sits anteriorly in 
Schlemm’s canal. Suture tension is then assessed by pulling the suture knot posteriorly, 
until it is only barely able to reach the scleral spur. Suture tension is felt to play an important 
role in canaloplasty, where a greater suture tension results in more distension of Schlemm’s 
canal with resultant greater IOP reduction and increased flow. The superficial scleral flap is 
then placed back into position and sutured in a watertight fashion with interrupted 10–0 
nylon sutures. Conjunctiva is also closed in a water tight fashion with 10-0 vicryl sutures. 
Complications 
In trabeculectomy the natural anterior chamber fluid outflow is by-passed via an artificial 
fistula. Unlike trabeculectomy, canaloplasty attempts to re-establish the physiological anterior 
chamber fluid draining system by means of dilation of Schlemm's canal and its collector 
channels. If the anterior chamber pressure temporarily lowers the level of the venous 
capillary pressure, it is consistent with a patent piping system when a reverse flow with 
blood reflux into the anterior chamber can be observed as long as a minimal physiological 
pressure gradient from the anterior chamber in the direction of channel Schlemm's canal has 
been restored. Thus, an anterior chamber haemorrhage shows the desired consistency of the 
draining system and hence it should logically be expected after each successful procedure 
where hypotony in the postoperative period occurs. (Koch et al., 2010) 
The surgery is technically challenging and hence there is a learning curve. Microhyphema 
(7.9%), early and late IOP elevations (7.9% and 2.4%, respectively), wound hemorrhage 
(2.4%), suture extrusion (1.6%), Descemet membrane detachment (DMD) (1.6%), and 
hypotony (0.8%) have been reported. (Grieshaber et al., 2010; Palmiero et al., 2010) 
Trabeculo-Descemet window fibrosis may occur in postoperative course. 
5.8 Scientific evidence so far 
Lewis and coworkers reported 3-year results of the safety and efficacy of canaloplasty either 
as a standalone procedure or in combination with cataract surgery in adult open angle 
glaucoma subjects. (Lewis et al., 2011) Three years postoperatively, all study eyes (n = 157) 
had a mean IOP of 15.2 mm Hg ± 3.5 (SD) and mean glaucoma medication use of 0.8 ± 0.9 
compared with a baseline IOP of 23.8 ± 5.0 mm Hg on 1.8 ± 0.9 medications. Eyes with 
combined cataract-canaloplasty surgery had a mean IOP of 13.6 ± 3.6 mm Hg on 0.3 ± 0.5 
medications compared with a baseline IOP of 23.5 ± 5.2 mm Hg on 1.5 ± 1.0 medications. 
Intraocular pressure and number of medication, in all eyes were significantly decreased 
from baseline at every time point (P<0.001). Late postoperative complications included 
cataract (12.7%), transient IOP elevation (6.4%), and partial suture extrusion through the 
trabecular meshwork (0.6%). 
Koerber reported a comparative case series of 30 eyes of 15 adult patients with bilateral 
primary open-angle glaucoma who underwent canaloplasty in one eye and viscocanalostomy 
in the contralateral eye. (Koerber, 2011) With a follow-up period of 18 months, both the 
canaloplasty and viscocanalostomy groups showed statistically significant reductions in 
mean IOP (P<0.01) and number of supplemental medications (P<0.01) as compared with 
preoperative values. In the canaloplasty cohort, eyes had a mean IOP of 14.5±2.6 mm Hg on 
0.3±0.5 medications at 18 months postoperatively as compared with preoperative levels of 
26.5±2.7 mm Hg on 2.1±1.0 medications. In the viscocanalostomy cohort, eyes had a mean 
IOP of 16.1±3.9 mm Hg on 0.4±0.5 medications at 18 months as compared with preoperative 
levels of 24.3±2.8 mm Hg on 1.9±0.8 medications (P=0.02). No patient in either cohort 
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experienced significant complications. The author concluded that canaloplasty showed 
slightly better efficacy to viscocanalostomy in the reduction of IOP (P=0.02). 
Grieshaber and coworkers have shown that Canaloplasty produced a sustained long-term 
reduction of IOP in 60 eyes of black Africans with POAG independent of preoperative IOP. 
(Grieshaber et al., 2010) 
5.9 Place in surgical armamentarium 
The analogy of cardiac surgery is most appropriate to educate patients. In some patients, 
cardiac surgeons can stent or dilate the obstructed vessel with a less invasive angioplasty, 
while in others with more serious disease, surgeons may have to open the chest and perform 
a more complex procedure.” For glaucoma patients, this means transitioning from 
canaloplasty to trabeculectomy. 
6. Deeplight gold micro shunt 
Device 
The GMS (SOLX Ltd, Boston, Massachusetts) is a nonvalved flat-plate drainage device made 
from 24-K medical-grade (99.95%) gold. The device is composed of two leaflets fused 
together vertically concealing nine channels within the body that connect the anterior 
openings to the posterior ones (Figure 7). Two different models of the device exist, the GMS 
(XGS-5) and the GMS Plus (XGS-10), both measuring 5.2 mm long, 2.4 mm wide anteriorly 
and 3.2 mm wide posteriorly, but differing in weight and channel size. The XGS-5 model 
weighs 6.2 mg and is 60mm in thickness with the channels measuring 25mm in width and 
44mm in height while the XGS-10 model weighs 9.2 mg and the channels measure 25mm in 
width by 68mm in height. Aqueous humor from the anterior chamber exiting through the 
uveoscleral pathway to the suprachoroidal space is enhanced by this device by allowing 
fluid to travel both through the channels in the shunt and also around the body of the shunt. 
(Melamed et al., 2009) 
Indications 
The suprachoroidal space appears to be an excellent pathway option for those patients who 
have had failed trabeculectomy or Schlemm’s canal procedures. 
Contraindications 
• Recent angle closure glaucoma episode  
• Uveitic glaucoma, iridocorneal endothelial syndrome, traumatic glaucoma, or neovascular 
glaucoma  
• Other significant ocular disease, except cataract  
• Active ocular infection  
• Expected ocular surgery in next 12 months  
• No suitable quadrant for implant 
Surgical procedure 
After a 4 mm fornix-based conjunctival peritomy, an approximately 3.5 mm scleral incision 
is created 2 mm posterior to the limbus or slightly further posteriorly in high myopes (can 
be inserted in any quadrant but easier in superotemporal quadrant). The dissection is 
carried out to near full thickness depth, where the choroid is visible through a thin layer of 
sclera. A scleral pocket at 95% depth is then created by tunneling anteriorly towards the 
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scleral spur. At this point, a vertical incision is made into the choroidal space and a small 
amount of suprachoroidal anesthesia and viscoelastic are administered with a blunt 
cannula. Via a sideport incision viscoelastic is filled in the anterior chamber at the 
anticipated site of entry of the gold shunt. Alternatively, an AC maintainer can be used and 
an entry is made into the anterior chamber at the level of the scleral spur through the 
previously constructed scleral tunnel.  
 
5.2 mm Long
2.4 mm Wide
XGS-5: 40 Microns Thick
XGS-10: 60 Microns Thick 3.2 mm Wide  
Fig. 7. Gold microshunt 
 
 
Fig. 8. Cross-section of eye showing correct GMS position  
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The shunt is placed through the scleral incision, ensuring the head of the device is in the 
anterior chamber (Figure 8). Positioning of the shunt is achieved posteriorly in the 
suprachoroidal space using a sharp 27-gauge needle against the shunt to gently encourage it 
into the suprachoroidal pocket expanded previously by viscoelastic while grasping the 
wound with a toothed forceps. A “Push then pull” approach works well while inserting the 
shunt through scleral incision in the anterior chamber. 
Alternatively, an instrument such as a Sinskey hook can be utilized on the lateral 
positioning holes. All of the shunt openings on the posterior aspect should be concealed 
under the posterior scleral lip of the wound. The anterior aspect of the wound can also be 
manipulated through the anterior chamber to aid in positioning of the shunt. Intraoperative 
gonioscopy can help to confirm the proper and intended positioning of the gold shunt in the 
anterior chamber.  
The overlying scleral wound is tightly sutured with 4–5 interrupted 10-0 nylon sutures to 
ensure watertight closure, as subconjunctival reservoir is not the intended mode of filtration 
in this surgical procedure. Finally, a 10-0 vicryl horizontal mattress suture is placed to 
reappose conjunctiva. The crescent-shaped anterior aspect of the shunt consists of a 
positioning hole, which can be used to adjust shunt positioning with an instrument such as a 
Sinskey hook. The posterior aspect of the shunt likewise possesses two lateral wings for 
shunt manipulation. Flow is directed through and around the shunt via the natural pressure 
gradient from the anterior chamber to the suprachoroidal space. 
Placement of GMS in anterior chamber allows future access with 790nm Ti: sapphire laser 
and goniolens to selectively open specific windows. 
Complications 
Mild hyphema, hypotony, choroidal effusion, haemorrhage or detachment and shunt 
migration have been noted in few cases, in decreasing order of their occurrence. 
6.1 Surgical evidence so far 
Melamed and colleagues reported results of implantation of the GMS in 38 patients with 
uncontrolled glaucoma in a prospective 2-center study. (Melamed et al., 2009) The mean 
follow-up time was 11.7 months. The IOP decreased a mean (SD) of 9 mmHg from 27.6 (4.7) 
to 18.2 (4.6) mmHg (P <0.001). Surgical success was achieved in 30 patients (79%) (IOP >5 
and <22 mm Hg, with or without antiglaucoma medication). Eight patients had mild to 
moderate transient hyphema. 
Mastropasqua and co workers used in vivo confocal microscopy to show that successful 
GMS implantation significantly increased conjunctival microcysts density and surface at the 
site of the device insertion. (Mastropasqua et al., 2010) These findings suggest that the 
enhancement of the aqueous filtration across the sclera may be one of the possible outflow 
pathways exploited by the shunt. 
6.2 Place in surgical armamentarium 
The European Agency for the Evaluation of Medicinal Products (EMEA) gave this shunt CE 
approval in October 2005. It is undergoing Phase III trials in USA. The results till date 
appear promising. One of the advantages with gold micro-shunt is that in addition to 
working as an implantable microscopic shunt, the level of IOP control can be titrated by the 
laser. Additional micro channels can be opened with the laser in the clinicians’ office. 
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6.3 EYEPASS Bi-Directional glaucoma implant 
Device 
The Eyepass Bi-Directional glaucoma implant (GMP Vision Solutions, Inc.) consists of a dual 
6.0 mm long silicone tube bonded at 1 end for less than 1.0 mm, creating a Y-shape (Figure 
9). (Dietlein et al., 2008) The inner diameter of the silicone tube is 125 μm and the outer 
diameter is 250 μm, making the tube narrow enough to fit the lumen of the Schlemm canal. 
The implant is sterilized by gamma radiation and is a single-use device that should be 
stored at a temperature between 15°C and 30°C.  
 
 
Fig. 9. Eyepass bidirectional implant 
Surgical procedure 
It can be used as a standalone procedure or in combination with cataract surgery. After a 
fornix-based superomedial conjunctival dissection and a mild wet field cautery, a two-third 
thickness triangular scleral flap with a 4 mm basis is dissected. Before the Schlemm canal is 
unroofed, clear corneal cataract surgery is performed. This is followed by the Schlemm canal 
unroofing by dissecting a second scleral flap or by opening the canal with small Vannas 
scissors. Before the Eyepass device is implanted in both lumina of the Schlemm canal, the 
openings on both sides of the canal are dilated by gentle injection of an OVD such as sodium 
hyaluronate 1.0% [Healon] through a viscocanalostomy cannula. Thereafter, the arms of the 
“Y” are inserted into the lumina of the Schlemm canal without exerting pressure in the 
direction of the anterior chamber. After both ends are buried in the Schlemm canal, the 
bonded end is inserted into the anterior chamber via a paracentesis almost 1.0 mm from the 
trabecular meshwork, toward the center of the anterior chamber and under the scleral flap. 
The implant does not need to be secured by sutures. The scleral flap is sutured to a 
watertight fit using interrupted 10-0 nylon sutures. The conjunctiva is closed with 8-0 
polyglactin (Vicryl) sutures at the limbus. 
Complications 
The implant actually acts as a wick underneath the scleral flap, encouraging transscleral 
filtration in the early days after surgery; hence early postoperative hypotony may occur. 
Intraoperative perforation of the trabecular meshwork may also occur. Since this procedure 
entails conjunctival dissection, it may compromise other future ab-externo glaucoma surgery. 
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6.4 Surgical evidence so far 
Dietlein et al conducted a small study to evaluate the safety and pressure-reducing efficacy 
of the Y-shaped Eyepass glaucoma implant in 12 glaucoma and cataract patients and found 
that combined cataract surgery with Eyepass shunt implantation was safe and appeared to 
be beneficial in glaucomatous eyes with cataract not requiring a low target IOP. (Dietlein et 
al., 2008) Perforation of the trabecular meshwork during Eyepass implantation occurred in 2 
eyes requiring explantation and conversion to trabeculectomy. In the remaining 10 eyes, the 
mean maximum IOP was 30.4 mm Hg preoperatively, 12.0 mm 1 day postoperatively, 17.2 
mm Hg at 4 weeks, and 18.3 mm at the end of the preliminary follow-up. 
In case of trabecular meshwork perforation while inserting an arm of Eyepass, whether 
opening just 1 arm of the canal could achieve sufficient degree of surgical success is yet to be 
ascertained. Over the long term, the transscleral filtration seems to play a minor role in the 
IOP reducing effect of the Eyepass implant because of scarring and no antimetabolite 
induced favourable wound modulation. Role of antimetabolites to improve transscleral 
filtration is questionable at present. 
6.5 Place in surgical armamentarium 
The implant is currently undergoing Phase III trials. 
7. Cypass micro stent 
Device 
Cypass (Transcend) is made from a biocompatible material (polyimide) and features a 
unique delivery system. The CyPass is a micro-implantable device, 6 mm in length, with a 
small lumen of 300 ìm (Figure 10). It allows for an ab interno surgical approach, which spares 
the conjunctiva, does not penetrate the sclera and leaves the trabecular meshwork intact. 
Surgical procedure 
It is implanted in the suprachoroidal space through a clear corneal incision, which coincides 
with the phacoemulsification incision in combined procedures. A special inserter is used to 
make the distal end of the device penetrate into the suprachoroidal space, while the 
proximal collar remains in the anterior chamber. Three rings on the collar keep the device in 
place, preventing movement. 
 
 
Fig. 10. Cypass microstent 
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7.1 Scientific evidence so far 
Early clinical results, with the Cypass being placed in combination with cataract surgery 
(study by Transcend; unpublished data), showed promising results, with a 42% IOP 
decrease and a 60% decrease in medication use at six months. 
Ongoing clinical trials 
Combination cypass and cataract surgery trial (COMPASS): Transcend’s 480 patient 
domestic pivotal clinical trial, combines the Cypass and cataract surgery. Enrollment began 
in the second half of 2009 and the company hopes to complete it by the end of 2011 or in 
early 2012. 
Cypass clinical evaluation trial (CYCLE): This is a European prospective, non-randomized 
multi-center trial that includes “all-comers” with a goal to assess the Cypass in a broad 
variety of glaucoma patients.  
DUETTE: This is another European trial. Evaluating two different versions of the Cypass in 
a prospective and randomized study. 
Place in surgical aramamentarium 
Cypass has been found to have few and minor complications compared with filtering 
procedures. In addition, it is a repeatable procedure, which leaves an intact superior 
conjunctiva, allowing filtering procedures to be performed at a later stage in case of failure. 
Preliminary findings need to be confirmed in prospective trials with larger series, evaluating 
long-term results. 
8. Conclusion 
The current gold standard, trabeculectectomy, has done well for many medically refractory 
glaucoma patients in the past 40 years. Despite its efficacy in lowering IOP, relatively easy 
learning curve, it is fraught with not only short time but lifetime potential sight threatening 
issues. Glaucomatologists and bioengineers are leaving no stone unturned to find a better 
alternative which addresses the flaws of trabeculectomy. Ex-PRESS glaucoma filtration 
implant, Trabectome electrocautery device, iStent, Canaloplasty, Gold microshunt and 
Eyepass bidirectional valve are few milestones along the path of finding an ideal glaucoma 
device. Although for most devices, the studies are ongoing and the verdict on long term 
safety and efficacy is awaited, the future definitely seems promising. One size does not fit all 
in glaucoma. Much remains to be resolved about all these new innovative procedures in 
glaucoma. It is not wise to abandon time-tested trabeculectomy but it’s time to be more 
selective in choosing surgical procedures. 
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